Preprint / Version 1

Cytokine Storm in COVID-19 Patients, their Impact on Organs and the Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors

Authors

  • Mujahed I Mustafa Department of Biotechnology, University of Bahri, Khartoum
  • Abdelrahman H Abdelmoneim Faculty of Medicine, Alneelain University, Khartoum
  • Eiman M Mahmoud Department of Immunology, Ahfad University for women, Khartoum
  • Abdelrafie M Makhawi Department of Biotechnology, University of Bahri, Khartoum

DOI:

https://doi.org/10.21467/preprints.139

Abstract

The novel coronavirus in not only causing respiratory problems, it may also damage the heart, kidneys, liver and other organs; in Wuhan 14 to 30% of COVID-19 patients have lost their kidney function and now require either dialysis or kidney transplants. The novel coronavirus gains entry into humans by targeting ACE2 receptor that found on lung cells, which destroy human lungs through cytokine storms, this leads to hyper-inflammation, forcing the immune cells to destroy healthy cells. This is why some COVID-19 patients need intensive care. The inflammatory chemicals released during COVID-19 infection cause the liver to produce proteins that defend the body from infections. However, these proteins can cause blood clotting, which can clog blood vessels in the heart and other organs; as a result, the organs are deprived from oxygen and nutrients which could ultimately lead to multi-organ failure and subsequent progression to acute lung injury, acute respiratory distress syndrome and often death. However, a novel protein modification tool called the QTY code, that are similar in their structure to antibodies, which could provide a solution to excess cytokines, these synthetic proteins can be injected into the body to blind the excess cytokines generated by the cytokine storm; this will eventually remove the excessive cytokines and inhibit the severe symptoms caused by the COVID-19 infection. In this review we will focuses on cytokine storm in COVID-19 patients, their impact on the organs and the potential treatment by QTY code-designed detergent-free chemokine receptors.

Keywords:

COVID-19, ACE2 receptor, Cytokine Storm, Novel Coronavirus, Antibody-Like Fusion Protein

Downloads

Download data is not yet available.

References

T. Hampton, "Bats may be SARS reservoir," Jama, vol. 294, p. 2291, Nov 9 2005.

A. Banerjee, K. Kulcsar, V. Misra, M. Frieman, and K. Mossman, "Bats and Coronaviruses," Viruses, vol. 11, Jan 9 2019.

W. Li, Z. Shi, M. Yu, W. Ren, C. Smith, J. H. Epstein, et al., "Bats are natural reservoirs of SARS-like coronaviruses," Science, vol. 310, pp. 676-9, Oct 28 2005.

Q. Ye, B. Wang, J. Mao, J. Fu, S. Shang, Q. Shu, et al., "Epidemiological analysis of COVID-19 and practical experience from China," J Med Virol, Apr 1 2020.

R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, et al., "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding," Lancet, vol. 395, pp. 565-574, Feb 22 2020.

S. A. Meo, T. Al-Khlaiwi, A. M. Usmani, A. S. Meo, D. C. Klonoff, and T. D. Hoang, "Biological and Epidemiological Trends in the Prevalence and Mortality due to Outbreaks of Novel Coronavirus COVID-19," J King Saud Univ Sci, Apr 9 2020.

S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, et al., "The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application," Ann Intern Med, Mar 10 2020.

M. Varia, S. Wilson, S. Sarwal, A. McGeer, E. Gournis, E. Galanis, et al., "Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada," Cmaj, vol. 169, pp. 285-92, Aug 19 2003.

V. Virlogeux, V. J. Fang, M. Park, J. T. Wu, and B. J. Cowling, "Comparison of incubation period distribution of human infections with MERS-CoV in South Korea and Saudi Arabia," Sci Rep, vol. 6, p. 35839, Oct 24 2016.

W.-j. Guan, Z.-y. Ni, Y. Hu, W.-h. Liang, C.-q. Ou, J.-x. He, et al., "Clinical Characteristics of Coronavirus Disease 2019 in China," New England Journal of Medicine, 2020.

Y. Bai, L. Yao, T. Wei, F. Tian, D. Y. Jin, L. Chen, et al., "Presumed Asymptomatic Carrier Transmission of COVID-19," Jama, Feb 21 2020.

Z. Hu, C. Song, C. Xu, G. Jin, Y. Chen, X. Xu, et al., "Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China," Sci China Life Sci, vol. 63, pp. 706-711, May 2020.

N. van Doremalen, T. Bushmaker, D. H. Morris, M. G. Holbrook, A. Gamble, B. N. Williamson, et al., "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1," N Engl J Med, vol. 382, pp. 1564-1567, Apr 16 2020.

J. Sellner, P. Taba, S. Ozturk, and R. Helbok, "The need for neurologists in the care of COVID-19 patients," Eur J Neurol, Apr 23 2020.

K. Roe, "Explanation for COVID-19 infection neurological damage and reactivations," Transbound Emerg Dis, Apr 22 2020.

H. S. Markus and M. Brainin, "EXPRESS: COVID-19 and Stroke - A Global World Stroke Organisation perspective," Int J Stroke, p. 1747493020923472, Apr 20 2020.

T. J. Oxley, J. Mocco, S. Majidi, C. P. Kellner, H. Shoirah, I. P. Singh, et al., "Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young," N Engl J Med, Apr 28 2020.

R. M. Dafer, N. D. Osteraas, and J. Biller, "Acute Stroke Care in the Coronavirus Disease 2019 Pandemic," J Stroke Cerebrovasc Dis, p. 104881, Apr 17 2020.

C. A. Romero, M. Orias, and M. R. Weir, "Novel RAAS agonists and antagonists: clinical applications and controversies," Nat Rev Endocrinol, vol. 11, pp. 242-52, Apr 2015.

M. I. Abdelmageed, A. H. Abdelmoneim, M. I. Mustafa, N. M. Elfadol, N. S. Murshed, S. W. Shantier, et al., "Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach," bioRxiv, p. 2020.02.04.934232, 2020.

M. Enayatkhani, M. Hasaniazad, S. Faezi, H. Guklani, P. Davoodian, N. Ahmadi, et al., "Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study," J Biomol Struct Dyn, pp. 1-19, Apr 15 2020.

M. Bhattacharya, A. R. Sharma, P. Patra, P. Ghosh, G. Sharma, B. C. Patra, et al., "Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach," J Med Virol, Feb 28 2020.

V. Baruah and S. Bose, "Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV," J Med Virol, vol. 92, pp. 495-500, May 2020.

E. Prompetchara, C. Ketloy, and T. Palaga, "Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic," Asian Pac J Allergy Immunol, vol. 38, pp. 1-9, Mar 2020.

B. Shanmugaraj, K. Siriwattananon, K. Wangkanont, and W. Phoolcharoen, "Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)," Asian Pac J Allergy Immunol, vol. 38, pp. 10-18, Mar 2020.

R. Zhang, X. Wang, L. Ni, X. Di, B. Ma, S. Niu, et al., "COVID-19: Melatonin as a potential adjuvant treatment," Life Sci, vol. 250, p. 117583, Jun 1 2020.

B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, et al., "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19," N Engl J Med, Mar 18 2020.

M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, et al., "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor," Cell, vol. 181, pp. 271-280.e8, Apr 16 2020.

Z. Wang and X. Xu, "scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells," Cells, vol. 9, Apr 9 2020.

X. Lu, Q. Chen, K. Xu, Y. Chen, L. Cheng, F. Liu, et al., Patient-derived mutations impact pathogenicity of SARS-CoV-2, 2020.

Q. Ye, B. Wang, and J. Mao, "The pathogenesis and treatment of the `Cytokine Storm' in COVID-19," J Infect, Apr 10 2020.

D. Wu and X. O. Yang, "TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib," J Microbiol Immunol Infect, Mar 11 2020.

Y. Zhang, L. Yu, L. Tang, M. Zhu, Y. Jin, Z. Wang, et al., "A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System," Engineering (Beijing), Mar 20 2020.

M. Zhao, "Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies," Int J Antimicrob Agents, p. 105982, Apr 16 2020.

V. Q. Chau, E. Oliveros, K. Mahmood, A. Singhvi, A. Lala, N. Moss, et al., "The Imperfect Cytokine Storm: Severe COVID-19 with ARDS in Patient on Durable LVAD Support," JACC Case Rep, Apr 8 2020.

C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China," Lancet, vol. 395, pp. 497-506, Feb 15 2020.

P. A. Ascierto, B. Fox, W. Urba, A. C. Anderson, M. B. Atkins, E. C. Borden, et al., "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19," J Immunother Cancer, vol. 8, Apr 2020.

J. M. Michot, L. Albiges, N. Chaput, V. Saada, F. Pommeret, F. Griscelli, et al., "Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report," Ann Oncol, Apr 2 2020.

F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, et al., "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study," Lancet, vol. 395, pp. 1054-1062, Mar 28 2020.

L. Smeeth, S. L. Thomas, A. J. Hall, R. Hubbard, P. Farrington, and P. Vallance, "Risk of myocardial infarction and stroke after acute infection or vaccination," N Engl J Med, vol. 351, pp. 2611-8, Dec 16 2004.

P. E. Gallagher, C. M. Ferrario, and E. A. Tallant, "Regulation of ACE2 in cardiac myocytes and fibroblasts," Am J Physiol Heart Circ Physiol, vol. 295, pp. H2373-9, Dec 2008.

E. Mendoza-Torres, A. Oyarzun, D. Mondaca-Ruff, A. Azocar, P. F. Castro, J. E. Jalil, et al., "ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension," Ther Adv Cardiovasc Dis, vol. 9, pp. 217-37, Aug 2015.

L. Gattinoni, D. Chiumello, and S. Rossi, "COVID-19 pneumonia: ARDS or not?," Crit Care, vol. 24, p. 154, Apr 16 2020.

L. A. Perrone, J. K. Plowden, A. Garcia-Sastre, J. M. Katz, and T. M. Tumpey, "H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice," PLoS Pathog, vol. 4, p. e1000115, Aug 1 2008.

R. J. Jose, A. E. Williams, and R. C. Chambers, "Proteinase-activated receptors in fibroproliferative lung disease," Thorax, vol. 69, pp. 190-2, Feb 2014.

R. J. Jose and A. Manuel, "COVID-19 cytokine storm: the interplay between inflammation and coagulation," Lancet Respir Med, Apr 27 2020.

Y. Cheng, R. Luo, K. Wang, M. Zhang, Z. Wang, L. Dong, et al., "Kidney disease is associated with in-hospital death of patients with COVID-19," Kidney Int, vol. 97, pp. 829-838, May 2020.

C. Ronco and T. Reis, "Kidney involvement in COVID-19 and rationale for extracorporeal therapies," Nat Rev Nephrol, Apr 9 2020.

R. Durvasula, T. Wellington, E. McNamara, and S. Watnick, "COVID-19 and Kidney Failure in the Acute Care Setting: Our Experience From Seattle," Am J Kidney Dis, Apr 8 2020.

G. Pei, Z. Zhang, J. Peng, L. Liu, C. Zhang, C. Yu, et al., "Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia," J Am Soc Nephrol, Apr 28 2020.

G. Ianiro, B. H. Mullish, C. R. Kelly, H. Sokol, Z. Kassam, S. Ng, et al., "Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel," Lancet Gastroenterol Hepatol, vol. 5, pp. 430-432, May 2020.

D. Raoult, A. Zumla, F. Locatelli, G. Ippolito, and G. Kroemer, "Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses," Cell Stress, vol. 4, pp. 66-75, Mar 2 2020.

M. N. Bangash, J. Patel, and D. Parekh, "COVID-19 and the liver: little cause for concern," Lancet Gastroenterol Hepatol, Mar 20 2020.

L. Mao, H. Jin, M. Wang, Y. Hu, S. Chen, Q. He, et al., "Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China," JAMA Neurol, Apr 10 2020.

C. Cabello-Verrugio, M. G. Morales, J. C. Rivera, D. Cabrera, and F. Simon, "Renin-angiotensin system: an old player with novel functions in skeletal muscle," Med Res Rev, vol. 35, pp. 437-63, May 2015.

Z. Xu, L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, et al., "Pathological findings of COVID-19 associated with acute respiratory distress syndrome," Lancet Respir Med, vol. 8, pp. 420-422, Apr 2020.

N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., "A Novel Coronavirus from Patients with Pneumonia in China, 2019," N Engl J Med, vol. 382, pp. 727-733, Feb 20 2020.

L. A. Henderson, S. W. Canna, G. S. Schulert, S. Volpi, P. Y. Lee, K. F. Kernan, et al., "On the alert for cytokine storm: Immunopathology in COVID-19," Arthritis Rheumatol, Apr 15 2020.

N. Vaninov, "In the eye of the COVID-19 cytokine storm," Nat Rev Immunol, Apr 6 2020.

S. Zhang, F. Tao, R. Qing, H. Tang, M. Skuhersky, K. Corin, et al., "QTY code enables design of detergent-free chemokine receptors that retain ligand-binding activities," Proc Natl Acad Sci U S A, vol. 115, pp. E8652-e8659, Sep 11 2018.

S. Hao, D. Jin, S. Zhang, and R. Qing, "QTY code-designed water-soluble Fc-fusion cytokine receptors bind to their respective ligands," QRB Discovery, pp. 1-18, 04/09 2020.

Z. J. Miknis, E. Magracheva, W. Li, A. Zdanov, S. V. Kotenko, and A. Wlodawer, "Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1," J Mol Biol, vol. 404, pp. 650-64, Dec 10 2010.

I. Moraga, D. Richter, S. Wilmes, H. Winkelmann, K. Jude, C. Thomas, et al., "Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency," Sci Signal, vol. 8, p. ra114, Nov 10 2015.

C. Oswald, M. Rappas, J. Kean, A. S. Dore, J. C. Errey, K. Bennett, et al., "Intracellular allosteric antagonism of the CCR9 receptor," Nature, vol. 540, pp. 462-465, Dec 15 2016.

D. J. Thiel, M. H. le Du, R. L. Walter, A. D'Arcy, C. Chene, M. Fountoulakis, et al., "Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex," Structure, vol. 8, pp. 927-36, Sep 15 2000.

S. I. Yoon, B. C. Jones, N. J. Logsdon, and M. R. Walter, "Same structure, different function crystal structure of the Epstein-Barr virus IL-10 bound to the soluble IL-10R1 chain," Structure, vol. 13, pp. 551-64, Apr 2005.

H. R. Kwon, "Study of the Structure and Function of CXC Chemokine Receptor 2," 2010.

D. Levin, B. Golding, S. E. Strome, and Z. E. Sauna, "Fc fusion as a platform technology: potential for modulating immunogenicity," Trends Biotechnol, vol. 33, pp. 27-34, Jan 2015.

D. M. Czajkowsky, J. Hu, Z. Shao, and R. J. Pleass, "Fc-fusion proteins: new developments and future perspectives," EMBO Mol Med, vol. 4, pp. 1015-28, Oct 2012.

D. N. Mekhaiel, D. M. Czajkowsky, J. T. Andersen, J. Shi, M. El-Faham, M. Doenhoff, et al., "Polymeric human Fc-fusion proteins with modified effector functions," Sci Rep, vol. 1, p. 124, 2011.

Downloads

Posted

2020-06-29

Section

Coronavirus

Categories

License

Copyright (c) 2020 Mujahed Mustafa, Abdelrahman Abdelmoneim, Eiman Mahmoud, Abdelrafie Makhawi

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Any non-commercial use, distribution, adaptation, and reproduction in any medium is permitted as long as the original work is properly cited. However, caution and responsibility are required when reusing as the articles on the preprint server are not peer-reviewed. Readers are advised to check for the availability of any updated or peer-reviewed version.